

What is claimed is:

5 1. A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding apolipoprotein B, wherein said compound specifically hybridizes with and inhibits the expression of a nucleic acid molecule encoding apolipoprotein B.

10

 2. The compound of claim 1 which is an antisense oligonucleotide.

15

 3. The compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 17, 18, 19, 20, 21, 23, 24, 25, 27, 28, 30, 31, 32, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 45, 46, 48, 49, 50, 51, 52, 53, 55, 56, 57, 58, 59, 61, 62, 63, 66, 67, 69, 71, 73, 74, 75, 76, 78, 79, 81, 82, 83, 84, 86, 87, 88, 90, 93, 96, 101, 101, 20 102, 103, 105, 109, 111, 111, 114, 115, 116, 117, 118, 119, 120, 121 or 122.

25

 4. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

 5. The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

30

 6. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

 7. The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

35

T01080" 00000000

18. The method of claim 16 wherein the condition involves abnormal cholesterol metabolism.

19. The method of claim 16 wherein the condition is
5 atherosclerosis.

20. The compound of claim 1 targeted to a nucleic acid molecule encoding apolipoprotein B, wherein said compound specifically hybridizes with and inhibits the expression of the long form of a nucleic acid molecule encoding apolipoprotein B, ApoB-100.